Share Email Print

Proceedings Paper

Results of treatment of patients with advanced stomach cancer treated by combination of low-level laser therapy (LLLT) and other methods: ten-year experience
Author(s): V. A. Mikhailov
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

In 1988 we started our investigation on the influence of low-level laser on oncologic patient. Now we have an experience of application of LLLT on more than 700 patients with the confirmed diagnosis of cancer at different stage. We used LLLT on 112 with stomach cancer 4th stage before and after operation and on patients without operating interference. LLLT investigations, with a wavelength of 890 nm, have shown that the laser therapy before operation is most effective. Laser therapy activates the immune system by increasing T-active rosette-formed cells and T-helpers and by decreasing T-suppressor cells. Application of LLLT decreases postoperative complications by 11.86 percent after palliative operations; by 9.63 percent after non-radical operations. It also promotes more rapid restorations of the motility and improves general status of patients by 58.69 percent. Investigations of low-level radiation have shown that the life-span of patients with 4th stage stomach cancer who were treated by laser therapy before surgery was increased by 2.03 percent; for those who were treated by LLLT after surgery it was increased by 1.81 times and by 3.03 times in those who took LLLT without surgery.

Paper Details

Date Published: 28 June 2000
PDF: 5 pages
Proc. SPIE 4166, Laser Florence '99: A Window on the Laser Medicine World, (28 June 2000); doi: 10.1117/12.389508
Show Author Affiliations
V. A. Mikhailov, Moscow Scientific and Practical Ctr. of Laser Medicine (Russia)

Published in SPIE Proceedings Vol. 4166:
Laser Florence '99: A Window on the Laser Medicine World
Leonardo Longo; Alfons G. Hofstetter; Mihail-Lucian Pascu; Wilhelm R.A. Waidelich, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?